1. Home
  2. SKYE vs REFI Comparison

SKYE vs REFI Comparison

Compare SKYE & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • REFI
  • Stock Information
  • Founded
  • SKYE 2012
  • REFI 2021
  • Country
  • SKYE United States
  • REFI United States
  • Employees
  • SKYE N/A
  • REFI N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • REFI Real Estate Investment Trusts
  • Sector
  • SKYE Health Care
  • REFI Real Estate
  • Exchange
  • SKYE Nasdaq
  • REFI Nasdaq
  • Market Cap
  • SKYE 176.8M
  • REFI 306.0M
  • IPO Year
  • SKYE N/A
  • REFI 2021
  • Fundamental
  • Price
  • SKYE $5.89
  • REFI $16.02
  • Analyst Decision
  • SKYE Strong Buy
  • REFI Buy
  • Analyst Count
  • SKYE 4
  • REFI 4
  • Target Price
  • SKYE $19.25
  • REFI $17.33
  • AVG Volume (30 Days)
  • SKYE 386.3K
  • REFI 114.0K
  • Earning Date
  • SKYE 01-01-0001
  • REFI 08-07-2024
  • Dividend Yield
  • SKYE N/A
  • REFI 11.73%
  • EPS Growth
  • SKYE N/A
  • REFI 0.51
  • EPS
  • SKYE N/A
  • REFI 1.99
  • Revenue
  • SKYE N/A
  • REFI $55,477,705.00
  • Revenue This Year
  • SKYE N/A
  • REFI $15.73
  • Revenue Next Year
  • SKYE N/A
  • REFI $7.11
  • P/E Ratio
  • SKYE N/A
  • REFI $8.05
  • Revenue Growth
  • SKYE N/A
  • REFI 2.73
  • 52 Week Low
  • SKYE $1.44
  • REFI $13.86
  • 52 Week High
  • SKYE $19.41
  • REFI $17.65
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 34.36
  • REFI 58.46
  • Support Level
  • SKYE $5.95
  • REFI $15.17
  • Resistance Level
  • SKYE $6.83
  • REFI $16.47
  • Average True Range (ATR)
  • SKYE 0.82
  • REFI 0.28
  • MACD
  • SKYE 0.09
  • REFI 0.09
  • Stochastic Oscillator
  • SKYE 21.26
  • REFI 69.80

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About REFI Chicago Atlantic Real Estate Finance Inc.

Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.

Share on Social Networks: